ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2022
CONVINCE in the context of existing evidence on haemodiafiltration.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- High-volume online hemodiafiltration versus high-flux hemodialysis: a short review of recent evidence and a discussion on clinical implementation.Kidney research and clinical practice · 2025Article
- Impact of convective clearance on intra-dialytic potassium removal in chronic dialysis patients.Artificial organs · 2025Observational
- Real-world effectiveness of hemodialysis modalities: a retrospective cohort study.BMC nephrology · 2025Article
- Hemoincompatibility in Hemodialysis-Related Therapies and Their Health Economic Perspectives.Journal of clinical medicine · 2024Article
- Middle Molecular Uremic Toxin and Blood Purification Therapy.Journal of clinical medicine · 2024Review
- Proceedings of a membrane update symposium: advancements, scientific insights, and future trends for dialysis membranes for enhanced clinical outcomes in end stage kidney disease patients.Frontiers in nephrology · 2024Article
- Will another trial CONVINCE nephrologists to adopt high-dose haemodiafiltration over conventional haemodialysis?Clinical kidney journal · 2023Article
- Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration.Clinical kidney journal · 2023Article
- Hemodiafiltration: Technical and Medical Insights.Bioengineering (Basel, Switzerland) · 2023Review
- Uremic toxins in chronic kidney disease highlight a fundamental gap in understanding their detrimental effects on cardiac electrophysiology and arrhythmogenesis.Acta physiologica (Oxford, England) · 2022Review
- On-line hemodiafiltration therapy for end-stage kidney disease patients: Promises for the future? What's next?Seminars in dialysis · 2022Article
- The impact of hemodiafiltration on cognitive function in patients with end-stage renal disease.Frontiers in neuroscience · 2022Article
- Controversy on the CONVINCE study findings: the PRO take.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haemodiafiltration (HDF) provides a greater removal of larger solutes and protein-bound compounds than conventional high-flux haemodialysis (HD). There are indications that the patients receiving the highest convection volumes of HDF result in improved survival compared with HD. However, the comparative efficacy of HDF versus HD remains unproven. Here we provide a comparative account of the methodology and aims of 'the comparison of high-dose HDF with high-flux HD' (CONVINCE) study in the context of the totality of evidence and how this study will contribute to reaching a higher level of certainty regarding the comparative efficacy of HDF versus HD in people with end-stage kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.